# EDGAR Filing Document

**Accession Number:** 0001661059
**File Stem:** 0001104659-25-071121
**Filing Date:** 2025-7
**Character Count:** 2691
**Document Hash:** 787932895630f9a4d01c17c675a24ae3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-071121.hdr.sgml**: 20250826

**ACCESSION NUMBER**: 0001104659-25-071121

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705

![](tm2521171d3_correspimg001.jpg)

9000 Virginia Manor Road, Suite 200

Beltsville, Maryland 20705

Tel : (240) 399-4900

July 28, 2025

<u>Via EDGAR</u>

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Tim Buchmiller

---

| | | | |
|:---|:---|:---|:---|
| Re: | NextCure, Inc. | NextCure, Inc. | NextCure, Inc. |
|  | Registration Statement on Form S-3 | Registration Statement on Form S-3 | Registration Statement on Form S-3 |
|  | File No. 333-288763 | File No. 333-288763 | File No. 333-288763 |
|  | **Acceleration Request** | **Acceleration Request** | **Acceleration Request** |
|  |  | **Requested Date:** | **July 29, 2025** |
|  |  | **Requested Time:** | **4:00 P.M., Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, NextCure, Inc. (the "***Company***") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (the "***Registration Statement***"), be accelerated so that the Registration Statement will become effective at 4:00 P.M., Eastern Time, on July 29, 2025, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

Please contact Kostian Ciko of Sidley Austin LLP at (212) 839-5450 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.

---

| |
|:---|
| Very truly yours, |
| /s/ Michael Richman |
| Michael Richman |
| Chief Executive Officer |
| NextCure, Inc. |

---

cc: Steven Cobourn, NextCure, Inc. <br> Asher Rubin, Sidley Austin LLP <br> Istvan A. Hajdu, Sidley Austin LLP